Remdesivir and Favipiravir Changes Hepato-Renal Profile in COVID-19 patients: A Cross Sectional Observation in Bangladesh

Background: Coronavirus disease (COVID-19) is the current global public health concern. Till date no specific, effective, and approved treatment available. With the rapid increase in rate of infection, repurposing use of anti- viral like remdesivir and favipiravir were considered as an option to find the promising anti-COVID therapeutics. In this study, we aim to observe hepato-renal safety concerns related to these drugs. Method: A retrospective study done from May 17 to September 9, 2020 on total 1348 hospital records. 182 patients were included in the study, devided into two groups who recieved remdesivir only (RO) and favipiravir only (FO). Result: Mean age of respective groups are 59.42 (RO) and 54.64 (FO). Average duration of hospital stay was 11 to 12 days. Mortality rate (28.39%) was higher in RO group. Mean± SD of both ALT (70.65± 50.25) and AST (62.25± 25.46) level was increased in RO group than FO group. On the other hand, Blood urea (56.67± 38.40) and serum creatinine (01.70± 02.41) level was higher in FO group. Hematuria was absent in both group, proteinuria was also unremarkable. Conclusion: In patients with Covid-19 receive remdesivir and favipiravir, showed elevation in the level of hepato- renal markers.